title: Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.
authors.forename: John A
authors.initials: JA
authors.lastname: Kiayias
authors.forename: Eugenia D
authors.initials: ED
authors.lastname: Vlachou
authors.forename: Eleni
authors.initials: E
authors.lastname: Theodosopoulou
authors.forename: Elli
authors.initials: E
authors.lastname: Lakka-Papadodima
mesh_terms: D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D000077154:Rosiglitazone; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008687:Metformin; D000077154:Rosiglitazone; D013453:Sulfonylurea Compounds; D013844:Thiazoles; D045162:Thiazolidinediones; C057619:glimepiride